Drug Profile
Research programme: CNS disorder therapeutics - JCR Pharmaceuticals/Eisai
Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Eisai Co Ltd; JCR Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for research development in CNS-disorders in Japan (IV, Injection)
- 21 Jul 2015 JCR Pharmaceuticals and Eisai concludes feasibility study agreement for the application of J-Brain Cargo technology to CNS disorders therapeutics
- 21 Jul 2015 Early research in CNS disorders in Japan (IV)